MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor (MOVE)

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.

This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Inclusion Criteria:

1. Diagnosis of TGCT according to medical records
2. Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated.
3. Has provided informed consent and medical records release

Exclusion Criteria:

1. Participant is active in an interventional clinical trial of vimseltinib